We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+11.77%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$894M
AUM Growth
-$76.8M
Cap. Flow
-$55.1M
Cap. Flow %
-6.17%
Top 10 Hldgs %
76.13%
Holding
32
New
–
Increased
2
Reduced
6
Closed
1

Top Buys

Rank Stock Value
1
SVRA icon
Savara
SVRA
+$9.31M
2
TNGX icon
Tango Therapeutics
TNGX
+$5.92M

Top Sells

Rank Stock Value
1
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$21.2M
2
DVAX
Dynavax Technologies
DVAX
+$21.1M
3
CBAY
Cymabay Therapeutics
CBAY
+$21M
4
THRD
Third Harmonic Bio
THRD
+$3.08M
5
TVRD
Tvardi Therapeutics
TVRD
+$2.37M

Sector Composition

Rank Sector Weight
1 Healthcare 98.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLO icon
26
Xilio Therapeutics
XLO
$59.6M
$5.92M 0.66%
200,387
– –
TSVT
27
DELISTED
2seventy bio
TSVT
$5.52M 0.62%
1,408,901
– –
IVVD icon
28
Invivyd
IVVD
$216M
$3.29M 0.37%
1,937,207
– –
CCCC icon
29
C4 Therapeutics
CCCC
$480M
$3.05M 0.34%
1,642,210
– –
NAMSW icon
30
NewAmsterdam Pharma Warrant
NAMSW
$78.2M
$190K 0.02%
100,000
– –
TVRD
31
Tvardi Therapeutics
TVRD
$22.1M
$39.7K ﹤0.01%
657
-25,312
-97% -$2.37M
THRD
32
DELISTED
Third Harmonic Bio
THRD
– –
-640,631
Closed -$3.08M
1
2

Similar funds

JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AIM
Advyzon Investment Management Lisle, Illinois $1.12B AUM 22.08% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 18.84% 1-Year Est. Return
CNC
Canandaigua National Corp Canandaigua, New York $1.12B AUM

Bain Capital Life Sciences Investors's Q3 2023 Portfolio in Review

As of Q3 2023, Bain Capital Life Sciences Investors held 32 positions worth $894M, down 7.9% from $971M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Bain Capital Life Sciences Investors withdrew a net $55.1M in Q3 2023, closing 1 position and reducing 6 holdings. Its most notable exit was Third Harmonic Bio, an estimated $3.08M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier.

Against the trend, Bain Capital Life Sciences Investors added an estimated $9.31M to Savara.

  • Bain Capital Life Sciences Investors added most to Savara in Q3 2023, an estimated $9.31M increase.
  • Bain Capital Life Sciences Investors's biggest Q3 2023 reduction was Crinetics Pharmaceuticals, cutting an estimated $21.2M.
  • Bain Capital Life Sciences Investors fully exited Third Harmonic Bio in Q3 2023, selling an estimated $3.08M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 76% of its $894M portfolio in Q3 2023.
  • Bain Capital Life Sciences Investors opened 0 new positions and closed 1 in Q3 2023.
  • Bain Capital Life Sciences Investors's portfolio value fell 7.9% quarter-over-quarter to $894M.

Based on Bain Capital Life Sciences Investors's 13F filing for Q3 2023, filed 14 Nov 2023.